AARDEX and Ondosis Partner to Revolutionize Precision Dosing and Optimize Drug Exposure in Clinical Trials

Liège, Belgium and Gothenburg, Sweden – October 15, 2024: AARDEX Group, a leader in managing drug exposure in clinical trials, and precision medicine innovators, and OnDosis, a game changer in precision dosing of oral solid medicines through the novel Dosage Manager device, have announced a partnership aimed at revolutionizing precision dosing and optimizing exposure-response in clinical trials. This collaboration is set to bring next-level innovation to drug development, ensuring more effective and safer treatments for patients.

As the pharmaceutical industry continues to advance, the drugs in development are becoming increasingly powerful pin targeting complex diseases. However, this growing potency presents challenges in managing variability between and within patients, which can make it difficult to achieve consistent, optimal drug exposure. Achieving and maintaining the correct dosage, especially for drugs with narrow therapeutic windows, is crucial in ensuring patient safety and treatment efficacy.

Bernard Vrijens, CEO, AARDEX Group commented; "With our joint expertise, we aim to improve the precision of dose-finding studies and optimize drug exposure throughout the entire clinical trial process. This will not only accelerate the identification of the optimal therapeutic dose but also lead to more successful confirmatory trials."

Martin Olovsson, CEO, OnDosis commented; “Combining the capabilities of the two organizations will create true synergies, with the ability to capture and understand drug exposure to optimize dosing combined with seamless, blinded dose adjustments and dose flexibility, thereby closing the loop between dose and outcomes with the potential for increased success in drug development.”

Through this partnership, AARDEX and OnDosis are combining their expertise to support pharmaceutical companies in navigating the complexities of drug development, from early-phase trials to market approval. With a shared commitment to patient safety and innovation, the two companies are paving the way for a new era of personalized, precision dosing in clinical trials.

About AARDEX Group. AARDEX Group is a global leader in managing medication adherence and drug exposure in clinical trials. With more than 30 years of experience, AARDEX delivers state-of-the-art digital tools and monitoring solutions that help pharmaceutical companies and researchers ensure precise and consistent medication use throughout the trial process. Their innovative technologies are key to improving patient outcomes and speeding up the path to drug approval, helping to streamline clinical research and support the development of effective therapies.

About OnDosis. A MedTech company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage—individualized, intuitive, and intelligent—in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device, the Dosage Manager, that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies. By combining traditional drug-based treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve. www.ondosis.com

For more information, please contact:

Bernard Vrijens
CEO, Aardex Group
Tel: +32 47 454 56 73, bernard.vrijens@aardexgroup.com

Martin Olovsson

CEO, OnDosis

Tel: +46 76 772 85 01, m.olovsson@ondosis.com